MedPath

Clinical efficacy observation of TCM in the prevention and treatment of macronodular cirrhosis (precancerous lesions)

Phase 1
Conditions
macronodular cirrhosis
Registration Number
ITMCTR1900002313
Lead Sponsor
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1.Patients with chronic hepatitis B cirrhosis who meet the diagnostic criteria;
2.Hepatic regenerative nodules (> 3 mm) were detected by B-mode ultrasonography and MRI.
3.Age ranges from 18 to 65 years, gender is not limited.
4.Sign informed consent.

Exclusion Criteria

(1) Patients with cirrhosis caused by other hepatophilic virus infection or other pathogenic factors;
(2) The presence or suspected presence of primary hepatocellular carcinoma lesions was detected by B-mode ultrasonography and MRI.
(3) The patients with decompensated cirrhosis, such as those with Child-Pugh C grade > 12 points, had upper gastrointestinal bleeding, hepatic encephalopathy, intractable ascites, hemorrhagic tendency, hepatorenal syndrome and primary hepatocellular carcinoma in the past six months.
(4) Patients with severe primary diseases of heart, kidney, lung, endocrine, blood, metabolism and gastrointestinal tract; or psychiatric patients.
(5) Pregnant women or breast-feeding women who are willing to have children in the near future.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Incidence and mortality of severe hepatitis;Incidence of primary liver cancer;Incidence of upper gastrointestinal hemorrhage, hepatic encephalopathy and hepatorenal syndrome;
Secondary Outcome Measures
NameTimeMethod
CBC;Virological indicators;Ultrasound/MRI of Upper Abdomen;TCM Syndrome Scale and Quality of Life Scale;Alpha fetoprotein;Fibroscan;Liver function;
© Copyright 2025. All Rights Reserved by MedPath